Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

This article was originally published in Scrip

Executive Summary

'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.

Advertisement

Related Content

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register